Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.

about

EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity.

P2860

Q37497677-BB8CB4E1-D4DA-4869-9C09-2260148AF42F Q50946920-F9B2350E-C80F-486D-903B-2FBEAD09F5DE

P2860

Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.

Item

http://www.wikidata.org/entity/Q38416816

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cardio-oncology Part II: the m ...... otherapeutic cardiac toxicity.

@en

type

Item

label

Cardio-oncology Part II: the m ...... otherapeutic cardiac toxicity.

@en

prefLabel

Cardio-oncology Part II: the m ...... otherapeutic cardiac toxicity.

@en

P1476

Cardio-oncology Part II: the m ...... otherapeutic cardiac toxicity.

@en

P2093

Ashwini Sharma

http://www.w3.org/2001/XMLSchema#string

Farouk Mookadam

http://www.w3.org/2001/XMLSchema#string

Howard Lee

http://www.w3.org/2001/XMLSchema#string

Katie Murphy

http://www.w3.org/2001/XMLSchema#string

Meabh O'Hare

http://www.w3.org/2001/XMLSchema#string

P2860

Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors

Cardiac dysfunction in the trastuzumab clinical trials experience

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

The role of cardiovascular magnetic resonance in heart failure.

P304

519-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2015.1027686

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25864865

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.

about

P2860

P2860

Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921